Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group halts shares ahead of capital raising

The company recently appointed Canadian Luke Pigeau as master grower.
asx sign
Further details regarding the capital raising are expected within 48 hours

AusCann Group Holdings Ltd (ASX:AC8) has been granted a trading halt by the ASX pending the release of information regarding a capital raising.

Shares in the company will remain halted until the earlier of the release of the relevant information or the commencement of trading on Thursday.

READ: AusCann Group Holdings to accelerate medical cannabis strategy through master grower appointment

Last week AusCann outlined that it intended to accelerate its Australian medical cannabis manufacturing operation through the appointment of Canadian Luke Pigeau as master grower.

Pigeau, who was appointed following an extensive global search, will oversee AusCann’s Tasmanian Alkaloids cultivation operation in Tasmania.

The appointment is complemented by the company entering into a research and development agreement with Canadian group Jade Cannabis.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
researcher filling a vial
April 24 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use